Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neuroblastoma 3Triple Negative Breast Neoplasms 2Melanoma 2Lung Neoplasms 2Ganglioneuroblastoma 2Transplant-Related Hematologic Malignancy 1Recurrence 1Prostatic Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Locally Advanced Pancreatic Adenocarcinoma 1Leukemia, Plasma Cell 1Leukemia 1Hodgkin Disease 1Gliosarcoma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Adenoma, Islet Cell 1

Interventions

Specimen Handling 4Magnetic Resonance Spectroscopy 4Sunitinib 2Everolimus 2sargramostim 1montanide ISA 51 1lutetium Lu 177 dotatate 1lanreotide 1incomplete Freund's adjuvant 1fludarabine phosphate 1cabozantinib 1belzutifan 1X-Rays 1Temozolomide 1Phantoms, Imaging 1Octreotide 1Methods 1Interleukin-13 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Colony-Stimulating Factors 1Blood Specimen Collection 1Biopsy 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × sargramostim × 90 days × Clear all
NCT06202066 2026-05-28

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Roswell Park Cancer Institute

Phase 2 Recruiting
60 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡